deferiprone
Ferriprox
Pharmaceutical company: Chiesi USA
NEW AVAILABLE FORMS
Oral solution: 80 mg/mL
Tablets: 1,000 mg for t.i.d. dosing; 1,000 mg for b.i.d. dosing
INDICATION & DOSAGE
Treatment of transfusional iron overload in patients with thalassemia syndromes
Adults and children age 8 and older: Initially, 25 mg/kg tablets or oral solution PO t.i.d., or 25 mg/kg tablets PO b.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 500 mg (one-half 1,000-mg tablet), 250 mg (one-half 500-mg tablet) or 2.5 mL of oral solution.
Children age 3 and older: Initially, 25 mg/kg oral solution PO t.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 2.5 mL of oral solution.
Treatment of transfusional iron overload in patients with sickle cell disease or other anemias
Adults and children age 8 and older: Initially, 25 mg/kg tablets or oral solution PO t.i.d., or 25 mg/kg tablets PO b.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 500 mg (one-half 1,000-mg tablet), 250 mg (one-half 500-mg tablet) or 2.5 mL of oral solution.
Children age 3 and older: Initially, 25 mg/kg oral solution PO t.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 2.5 mL of oral solution.
Adjust-a-dose (for both indications): To minimize GI upset when initiating therapy, may start at 45 mg/kg/day and increase weekly by 15 mg/kg/day. If serum ferritin level falls consistently below 500 mcg/L, consider temporary therapy interruption. For ANC less than 1,500/mm3, interrupt therapy immediately and monitor until recovery; do not rechallenge unless the potential benefit outweighs the risk. For ANC less than 500/mm3, consider hospitalization and other clinically appropriate management; do not resume unless potential benefits outweigh the risks.
Released: September 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
posaconazole
Noxafil
Pharmaceutical company: Merck Sharp & Dohme
NEW INDICATION & DOSAGE
Treatment of invasive aspergillosis
Adults and children ages 13 to 17: 300-mg delayed-release tablet PO b.i.d. on first day, then 300 mg PO once daily. Or, 300 mg IV b.i.d. on first day, then 300 mg IV once daily for 6 to 12 weeks. May switch between IV and delayed-release tablets; no loading dose is required when switching between formulations.
Released: September 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
secnidazole
Solosec
Pharmaceutical company: Lupin Pharmaceuticals
NEW INDICATION & DOSAGE
Treatment of trichomoniasis
Adults: One single dose of 2 g PO. Treat sexual partners at same dose at same time.
Released: September 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
sugammadex
Bridion
Pharmaceutical company: Merck Sharp & Dohme
NEW INDICATION & DOSAGE
Reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in patients undergoing surgery
Children age 2 and older (routine reversal of rocuronium and vecuronium-induced neuromuscular blockade): Base doses and timing of drug administration on twitch responses and extent of spontaneous recovery. Give 4 mg/kg IV bolus over 10 seconds if recovery of twitch response has reached one to two posttetanic counts and there are no twitch responses to train-of-four (TOF) stimulation. Give 2 mg/kg IV bolus over 10 seconds if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation.
Alert: Immediate reversal of rocuronium-only induced neuromuscular blockade has not been studied in children.
Released: September 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer